Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Inovio licenses preclinical T cell therapies
June 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BLUE PELL, Pa.—Inovio Pharmaceuticals Inc. has announced the acquisition of worldwide rights (excluding China) to early preclinical therapies addressing multiple sclerosis and Alzheimer’s disease based on the academic research of Dr. Bin Wang, a professor at Fudan University’s Shanghai Medical College. In consideration for the rights, Inovio will make clinical and regulatory milestone payments to Fudan University. The work by Wang and his collaborator is the result of their discovery of a novel way to generate inducible regulatory T cells, or iTreg, which help to shut down immune responses after a threat is eliminated. These cells also help to prevent autoimmune or inflammatory diseases. In preclinical studies, this approach generated CD25-iTreg in an antigen-specific manner, and could hold the potential to treat major inflammatory diseases such as multiple sclerosis.
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.